Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
نویسندگان
چکیده
Harriet L. Robinson and Kent J. Weinhold Emory Vaccine Center and Division of Microbiology and Immunology, Yerkes Primate Research Center and Emory University Center for AIDS Research, Emory University, Atlanta, Georgia; Department of Surgery and Immunology and the Duke University Center for AIDS Research, Duke University, Durham, North Carolina (See the articles by Catanzaro et al. and by Graham et al., on pages 1638–49 and 1650–60, respectively.)
منابع مشابه
Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials
1 Duke University, Center for AIDS Research Central QA Unit, Durham, North Carolina, United States of America, 2 International AIDS Vaccine Initiative, Rockville, Maryland, United States of America, 3 Henry M. Jackson Foundation for the Advancement of Military Medicine–Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health an...
متن کاملA Shot at Dendritic Cell-Based Vaccine Strategy against HIV-1
Introduction: Despite considerable efforts to control AIDS pandemic, it is still one of the significant infectious concerns worldwide. The advance in medical research has led to the development of highly active antiretroviral therapy with a considerable effect to suppress the disease. However, an effective vaccine capable of eradication the HIV pandemic is not available yet. Failure to develop ...
متن کاملThe development of an AIDS vaccine: progress and promise.
The development of a safe and effective vaccine against infection by the human immunodeficiency virus (HIV) is of paramount importance to the prevention of AIDS worldwide. Although a great deal has been learned about HIV in a few short years, the development of an AIDS vaccine has proved to be extremely difficult. The lack of an appropriate animal model for AIDS, the absence of a defined protec...
متن کاملRecommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.
Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines John R. Mascola,* Patricia D’Souza, Peter Gilbert, Beatrice H. Hahn, Nancy L. Haigwood, Lynn Morris, Christos J. Petropoulos, Victoria R. Polonis, Marcella Sarzotti, and David C. Montefiori Vaccine Research Center and Divisi...
متن کاملAn HIV vaccine: how and when?
The best long-term hope for controlling the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pandemic is a safe, effective and affordable preventive vaccine, but its development has encountered unprecedented scientific challenges. The first phase I trial of an HIV vaccine was conducted in 1987. Subsequently, more than 30 candidate vaccines have been tested in over 60 p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of infectious diseases
دوره 194 12 شماره
صفحات -
تاریخ انتشار 2006